Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clinical Trial
Official title:
Phase 2 Study to Assess the Safety and Efficiency of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Phase Chronic Myelogenous Leukemia Patients
The purpose of this study is to assess the safety and efficiency of adding pioglitazone to chronic phase chronic myelogenous leukemia patients having received imatinib mesylate who have acquired a stable molecular response but not complete molecular response.
Although tyrosine-kinase inhibitors have profoundly converted the outcomes of chronic myelogenous leukemia patients ,the most of who could have a complete cytogenetic response, a large majority of patients could not come to a complete molecular response that is undetectable in breakpoint cluster region-Abelson chimeric oncogene transcripts. According to some previous researches, pioglitazone may target leukemia stem cells and induce them into cell cycle making them exit from quiescent undivided states. Subsequently, pioglitazone may gradually erode leukemia stem cells leading to undetectable minimal residual disease. Thus the investigators expect to assess the safety and efficiency of pioglitazone in combination with imatinib mesylate in clinical trials. Maybe the combination therapy induce more patients in a detectable molecular response into a deeper molecular response. Furthermore, pioglitazone may be extensively adapted into the treatment of chronic phase chronic myelogenous leukemia patients as a common protocol. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01437202 -
Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia
|
N/A | |
Completed |
NCT02896842 -
A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML
|
Phase 2 | |
Withdrawn |
NCT02421926 -
Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
|
||
Completed |
NCT01768689 -
Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
|
N/A | |
Not yet recruiting |
NCT02903277 -
National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent
|
N/A | |
Completed |
NCT03090477 -
Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients
|
N/A | |
Active, not recruiting |
NCT02885766 -
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
|
Phase 1/Phase 2 | |
Recruiting |
NCT01464411 -
Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
|
N/A | |
Completed |
NCT01602952 -
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
|
Phase 1/Phase 2 | |
Completed |
NCT00171223 -
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
|
Phase 2 | |
Recruiting |
NCT04877522 -
Asciminib Roll-over Study
|
Phase 4 | |
Completed |
NCT01511289 -
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
|
Phase 3 | |
Completed |
NCT02480608 -
Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)
|
Phase 1/Phase 2 | |
Completed |
NCT02389972 -
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study
|
N/A | |
Completed |
NCT01774630 -
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
|
Phase 2 |